Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 8,445 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolism Disorder, Glucose Clear all
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

NCT00924053
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
EGT0001474, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Precision Diets for Diabetes Prevention

NCT03919877
View directory record Official record
Conditions
Pre Diabetes, Insulin Resistance, Diabetes Mellitus, Type 2
Interventions
Dietary, Oral Food Challege
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 7:24 PM EDT
Enrolling by invitation No phase listed Observational

Clinical Decision Support With Continuous Glucose Monitoring Data for Managing Type 2 Diabetes

NCT07394075
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Continuous Glucose Monitoring Clinical Decision Support
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Changing Lifestyles for Better Health

NCT00848757
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Intensive Lifestyle Intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

NCT01334151
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Insulin LISPRO, recombinant human insulin
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 21, 2026, 7:24 PM EDT
Recruiting Early Phase 1 Interventional

GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

NCT06338553
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Semaglutide (Rybelsus®), Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 21, 2026, 7:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lifestyle and Cardiometabolic Risk in Post-9/11 Veterans

NCT04911153
View directory record Official record
Conditions
PTSD, Cardiovascular Disease, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 21, 2026, 7:24 PM EDT
Terminated Not applicable Interventional

Sleeve Gastrectomy Versus Medical Management for Remission of Diabetes in Mild to Moderately Obese Patients

NCT00965302
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Laparoscopic sleeve gastrectomy, Intensive medical management
Procedure · Behavioral
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

NCT01845831
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk Factors

NCT02482922
View directory record Official record
Conditions
Pre-Diabetic, Overweight, Obesity
Interventions
Exercise & Dietary Supplement
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

NCT04776629
View directory record Official record
Conditions
Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
Interventions
Orticumab, Placebo
Drug
Lead sponsor
Abcentra
Industry
Eligibility
30 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Scottsdale, Arizona • Santa Monica, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Not applicable Interventional

Men Together Making a Difference: Health Promotion for Black Men

NCT02572414
View directory record Official record
Conditions
HIV, Cardiovascular Disease, Diabetes, Hypertension, Colon Cancer
Interventions
Health Promotion Intervention, Health Awareness Control Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years and older · Male only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Phase 2 Interventional

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00044694
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Placebo 0.01 mL, Placebo 0.02 mL, Placebo 0.03 mL, Placebo 0.04 mL, AC2993 2.5 mcg, AC2993 5.0 mcg, AC2993 7.5 mcg, AC2993 10.0 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Phase 3 Interventional

At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation

NCT02705053
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM and Insulin Pump, Closed-Loop Control System
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

NCT01991795
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Ticagrelor 60 mg, Ticagrelor placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
19,271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
295
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 238 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Not applicable Interventional

Nutritional Intervention to Prevent Diabetes

NCT00333554
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
DHA Treatment, Placebo for DHA
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Up to 5 Months
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Overcoming Barriers and Obstacles to Adopting Diabetes Devices

NCT04161131
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ONBOARD
Behavioral
Lead sponsor
Molly Tanenbaum
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Not applicable Interventional

Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm)

NCT00333853
View directory record Official record
Conditions
Diabetes
Interventions
OneTouch(r) UltraSmart(r)
Device
Lead sponsor
LifeScan
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2008 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Metabolic Effects of Switching Kaletra to Boosted Reyataz

NCT00413153
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/ritonavir, lopinavir/ritonavir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 21, 2026, 7:24 PM EDT
Completed No phase listed Observational

Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk

NCT07619495
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity, Overweight
Interventions
Semaglutide, Dulaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
120,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 21, 2026, 7:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Partnership Programs to Reduce Cardiovascular Disparities- Morehouse- Emory Partnership

NCT00336869
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
30 Years to 65 Years
Enrollment
680 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 21, 2026, 7:24 PM EDT
Recruiting Not applicable Interventional

A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)

NCT07355270
View directory record Official record
Conditions
Type-2 Diabetes Mellitus
Interventions
RF Vapor Ablation
Device
Lead sponsor
Aqua Medical, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Scottsdale, Arizona • Newport Beach, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 7:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studying Infant Nutrition and Blood Sugar

NCT03524469
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
19 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 21, 2026, 7:24 PM EDT
Completed Phase 4 Interventional

Early Diabetes Intervention Program

NCT01470937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Acarbose, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
25 Years to 80 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 21, 2026, 7:24 PM EDT